Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

It is not only good medical practice to ensure patients are fully involved in their treatment decisions, but it also improves subsequent compliance, and may even be cost effective. However, choosing treatments in MS is becoming increasingly complex, which means that ensuring patients understand all the issues is a challenge and time consuming. Preference sensitive care (which applies to current MS immunomodulatory treatments) is particularly vulnerable to the individual doctor's opinion and there is an onus on the physician to ensure the decision made incorporates the patient's individual values. National patient decision making tools are an appropriate solution to this dilemma and may, in the future, be a legal requirement in consent to treatment.

Original publication

DOI

10.1016/j.jns.2013.09.001

Type

Journal article

Journal

J Neurol Sci

Publication Date

15/12/2013

Volume

335

Pages

5 - 8

Keywords

Consent, Decision aids, Multiple sclerosis, Partnership, Preference sensitive care, Treatment choice, Decision Making, Humans, Multiple Sclerosis, Patient Participation, Physician-Patient Relations